Biphosphonates have long been the standard of care for antiresorptive treatment of bone metastases from castrate-resistant prostate cancer (mCRPC). Although the indication has historically been mostly palliative, response rates in skeletal-related events (SRE) remain low. Denosumab has been shown to be effective in prolonging time to first SRE in clinical settings, however, critical questions remain on its ability to affect bone metastases in mCRPC. The landscape for research progress in reducing SREs using novel pharmacotherapies is growing rapidly, with several agents in clinical trials. This focused review outlines the most promising investigational drugs for treating bone metastases in mCRPC.
|Number of pages||8|
|State||Published - Jul 2012|
- Bone metastases
- Prostate cancer (PCa)
- Skeletal related events (SRE)